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d The relative abundance of huntingtin 30 UTR isoforms
changes in Huntington’s disease
d Huntingtin 30 UTR isoforms are metabolized differently
d Many other genes associated with Huntington’s
pathogenesis exhibit isoform changes
d Knockdown of the CNOT6 RNA-binding protein recapitulates
some isoform alterations
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Romo et al. show that the abundance of
mRNA 30 UTR isoforms of huntingtin and a
subset of other genes changes in
Huntington’s disease motor cortex.
Genes with isoform alterations occur in
pathways implicated in disease
pathogenesis. Differential expression of
RNA-binding proteins may cause these
isoform changes in Huntington’s disease.
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SUMMARY
The huntingtin gene has two mRNA isoforms that
differ in their 30 UTR length. The relationship of these
isoforms with Huntington’s disease is not estab-
lished. We provide evidence that the abundance of
huntingtin 30 UTR isoforms differs between patient
and control neural stem cells, fibroblasts, motor cor-
tex, and cerebellum. Huntingtin 30 UTR isoforms,
including a mid-30 UTR isoform, have different local-
izations, half-lives, polyA tail lengths, microRNA
sites, and RNA-binding protein sites. Isoform shifts
in Huntington’s disease motor cortex are not limited
to huntingtin; 11% of alternatively polyadenylated
genes change the abundance of their 30 UTR iso-
forms. Altered expression of RNA-binding proteins
may be associated with aberrant isoform abun-
dance; knockdown of the RNA-binding protein
CNOT6 in control fibroblasts leads to huntingtin iso-
form differences similar to those in disease fibro-
blasts. These findings demonstrate that mRNA
30 UTR isoform changes are a feature of molecular
pathology in the Huntington’s disease brain.
INTRODUCTION
Huntington’s disease (HD) is a neurodegenerative disorder
caused by expansion of the CAG repeat in huntingtin (HTT)
exon 1 (Macdonald et al., 1993). The expansion is dominantly in-
herited and fully penetrant. Individuals usually develop symp-
toms in their mid-thirties, and death occurs within two decades
(reviewed in Suchowersky, 2014). Neurodegeneration starts in
the striatum and motor cortex, but it spreads to other brain re-
gions by the time of death (Vonsattel et al., 1985). Neuronal
toxicity is largely due to the effect of mutant HTT protein,
although mutant mRNA may also be toxic (Ban˜ez-Coronel
et al., 2015; DiFiglia et al., 1997; Li et al., 2008; Zuccato et al.,
2010). Emerging therapies aim to decrease mutant HTT mRNA
(Hu et al., 2010; Pfister et al., 2009).
Three isoforms of HTT mRNA are produced via alternative
polyadenylation. A truncated (7.9-kb) isoform is terminated at a
cryptic polyadenylation (polyA) signal in the first intron (Sathasi-
vam et al., 2013). This isoform is of low abundance. Its presence
in HD patients and mouse models, but not controls, suggests it
may be associated with disease (Sathasivam et al., 2013). The
two predominant HTTmRNA isoforms are generated by alterna-
tive polyadenylation in the 30 UTR (Lin et al., 1993). The short
(10.3-kb) 30 UTR isoform predominates in dividing cells, whereas
the long (13.7-kb) isoform predominates in nondividing cells (Lin
et al., 1993). It has not been established whether the relative
abundance of HTT mRNA 30 UTR isoforms changes in HD.
Although many genes exhibit expression and splicing differ-
ences in HD, 30 UTR isoform expression alterations have not
been investigated (Hodges et al., 2006; Labadorf et al., 2015;
Lin et al., 2016; Mykowska et al., 2011).
30 UTR length is important for mRNA localization, stability, and
translation (Di Giammartino et al., 2011). Many mRNAs use
30 UTR alternative polyadenylation to achieve tissue-specific
expression and function (Lianoglou et al., 2013; Smibert et al.,
2012; Zhang et al., 2005). Long isoforms contain binding sites
for trans-acting factors such as microRNAs that exert dynamic
changes in steady-state mRNA levels (Sandberg et al., 2008).
Ubiquitously expressed genes, like HTT, are the most likely to
use alternative polyadenylation to alter mRNA expression in
the brain (Lianoglou et al., 2013; Lin et al., 1993). Changes in
mRNA 30 UTR length occur in Parkinson’s disease and cancer
(Mayr and Bartel, 2009; Rhinn et al., 2012). We sought to deter-
mine if alterations in 30 UTR length are a feature of HD.
We provide evidence that the abundance ofHTTmRNA30 UTR
isoforms differs between HD patients and non-HD controls,
including a mid-length 30 UTR isoform. We show that HTT
30 UTR isoforms have different localizations, half-lives, polyA
tail lengths, microRNA sites, and RNA-binding protein sites. Iso-
form alterations in HD are not unique to HTT; there are wide-
spread changes in mRNA 30 UTR isoform expression in the HD
motor cortex. Genes with isoform changes are associated with
pathways that are dysfunctional in HD. Knockdown of the
CNOT6 RNA-binding protein leads to isoform shifts similar to
those in the HD motor cortex. Our findings indicate that altered
30 UTR isoform expression of HTT and a subset of other genes
is a feature of molecular pathology in the HD motor cortex.
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RESULTS
The Abundance of HTTmRNA 30 UTR Isoforms Changes
in HD
We identified two abundantHTTmRNA 30 UTR isoforms in public
30 sequencing data (Figure 1A) (Lianoglou et al., 2013). As in pre-
vious studies, we found HTT mRNA isoform abundance varies
across normal tissues: the longer isoform predominates in the
brain, neuronal precursor (NTERA2) cells, breast, and ovary,
whereas the shorter isoform predominates in testes, B cells,
muscle, and HEK293 cells (Figure 1B) (Lin et al., 1993).
To determine whether HTT mRNA isoform abundance
changes in HD, we performed qRT-PCR of the HTT long isoform
normalized to total HTT expression on patient cerebellum,
motor cortex, fibroblasts, and neural stem cells. HD cerebellum
samples were from grade 2, 3, or 4 brains, whereas motor cor-
tex samples were from grade 1 and 2 brains (Table S1). HD
brain grades are based on the degree of striatal degeneration.
Grades range from 1 (50% neuronal loss) to 4 (95% neuronal
loss) (Vonsattel et al., 1985). There is limited involvement of
the cerebellum in all grades (R€ub et al., 2013; Vonsattel, 2008;
Vonsattel et al., 1985). Cortical pathology is variable, but typi-
cally 10% of neurons are lost in grade 1 and up to 40% are
lost in grade 2 (Thu et al., 2010; Vonsattel et al., 1985). Neuronal
loss can confound gene expression studies. We chose to
analyze HTT isoform expression in the cortex and cerebellum
rather than in the striatum because neuronal loss is limited in
these regions.
We found a 1.6-fold increase in the long 30 UTR isoform relative
to total HTT mRNA in HD patient cerebellum. Conversely, there
was a 2.5-fold decrease in the long isoform in HD motor cortex
(Figure 1C). Patient fibroblasts and neural stem cells also ex-
hibited a decrease in the long isoform (Figure 1D; 2-fold and
3.3-fold, respectively). These results demonstrate that the abun-
dance of HTTmRNA 30 UTR isoforms changes in HD in a tissue-
and cell-specific manner.
HTTmRNA Isoform Changes Extend to Liver andMuscle
and Arise from Both Alleles
We used HDmodel mice to determine if disease-associated iso-
form changes extend beyond the brain. We bred mice that lack
murine Htt but harbor full-length human HTT, with either 18 or
128 CAG repeats on a yeast artificial chromosome (Yac18 and
Yac128) (Slow et al., 2003; Zeitlin et al., 1995). Like patients,
Yac128 cerebellum exhibited an increase (1.7-fold) in the long
HTT 30 UTR isoform compared to yac18 cerebellum. Isoform
differences extended to muscle (quadriceps) and liver, with a
2.2-fold increase and a 1.6-fold decrease in the HTT long
mRNA isoform, respectively (Figure 2A). These findings indicate
that at least two non-brain tissues exhibit tissue-specific HTT
mRNA isoform changes.
Altered HTT mRNA isoform abundance in HD brains could
arise from the wild-type allele, the mutant allele, or both. To
determine which allele is responsible for the changes, we per-
formed allele-specific qPCR on human cerebellum and motor
cortex samples heterozygous for SNP rs362267 in the HTT
Figure 1. HTT 30 UTR Isoforms Change Their Relative Amounts in HD
(A) NTERA2 cell 30-sequencing reads mapping to the HTT 30 UTR.
(B) Quantification of HTT 30 UTR isoform 30-sequencing reads relative to total HTT 30 UTR reads across human tissues and cells.
(C) Fold change in expression of theHTTmRNA long 30 UTR isoform (long) relative to totalHTT expression (total) between HD patient and control cerebellum (CB)
and motor cortex (MCx), measured by qPCR (*p < 0.05, **p < 0.005, and ***p < 0.0005).
(D) qPCR as in (C), using patient or control fibroblasts or neural stem cells (NSCs).
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long, but not short, 30 UTR. This SNP heterozygosity is not linked
to the CAG repeat; in some patients, the C allele is expanded
whereas in others the T allele is expanded. The long isoform
qPCR probe matched either the C or the T SNP. The amounts
of both the mutant and wild-type HTT long 30 UTR isoform
were changed in HD cerebellum and motor cortex compared
to controls (Figures 2B and 2C). The direction of isoform changes
was consistent between alleles in each patient (Figure 2D, corre-
lation coefficient 0.83). Thus, the change in HTTmRNA isoforms
arises from both alleles in HD.
PolyA Site Sequencing Identified a Conserved
Mid-30 UTR Isoform of HTT mRNA
To identify other 30 UTR isoforms of HTT, we used a high-quality
polyA site sequencing method (PAS-Seq) (Figures 3A, 3B, and
S1) (Ashar-Patel et al., 2017). PAS-Seq confirmed there was a
decrease in the long isoform (1.4-fold) in HD motor cortex,
whereas there was a decrease in the short isoform (1.8-fold) in
HD cerebellum (Figures 3G, 3H, and 3J). PAS-Seq identified a
third 12.5-kb isoform of HTT expressed in both control and HD
human cerebellum and motor cortex (Figure 3C, top). We per-
formed PAS-Seq on mice to test if this mid-30 UTR isoform is
conserved. We used wild-type and Q140 HDmice, which harbor
Figure 2. HTT Isoform Changes Extend to
Muscle and Liver, and Both HTT Alleles
Change 30 UTR Isoform Amounts in HD
(A) Fold change in expression of the HTT long
30 UTR isoform (long) relative to total HTT
expression (total) between Yac128 and Yac18
mouse tissues, measured by qPCR (*p < 0.05,
**p < 0.005, and ***p < 0.0005). CB, cerebellum.
(B) Allele-specific qPCR using SNP rs362267.
Shown is the fold change in the HTT long 30 UTR
isoform (long) relative to total HTT expression
between patient and control cerebellum.
(C) Allele-specific qPCR in patient and control
motor cortex, as in (B).
(D) Correlation of HTT allele expression within
each HD or control (con) cerebellum (CB) or motor
cortex (MCx); r = 0.83.
140 CAG repeats knocked into mouse
HTT (Menalled et al., 2003). All three
HTT 30 UTR isoforms were present in
wild-type and Q140 mice (Figure 3C, bot-
tom). There was a putative polyA signal
(AAUGAA) located 20 nt upstream of the
mid-30 UTR isoform polyA site (Sheets
et al., 1990; Tian et al., 2005). This polyA
signal and site were conserved between
mice and humans (Figure 3D). The re-
gions up- and downstream of the isoform
polyA sites were also conserved (Fig-
ure 3E). The abundance of the mid-30
UTR isoform varied across tissues and
increased 2.8-fold in HD motor cortex
compared to control (Figures 3F–3H).
Isoform changes cannot be explained
by gene expression alterations: total HTT expression was
decreased by 1.4-fold in HD motor cortex but unchanged in cer-
ebellum compared to controls (Figure 3I). In addition, isoform
changes were still significant after normalizing to total HTT
expression (Figure 3J).
HTTmRNA 30 UTR Isoforms Are Metabolized Differently
30 UTR length affectsmRNA localization, stability, and translation
(Di Giammartino et al., 2011). Isoform shifts in HDmay affectHTT
mRNA metabolism. To assay the localization of HTT 30 UTR iso-
forms, we performed isoform-specific qRT-PCR (Figures S2A
and S2B) on nuclear or cytoplasmic mRNA from SH-SY5Y (hu-
man neuroblastoma) cells and HD or control fibroblasts. SH-
SY5Y cells have neuronal characteristics, making them a model
of mRNA metabolism in the brain (Kovalevich and Langford,
2013). In SH-SY5Y cells, all HTT isoforms were three times
more abundant in the cytoplasm than in the nucleus, whereas
the cytoplasmic-to-nuclear expression ratio was lower in fibro-
blasts (Figure 4A). In fibroblasts, the HTT mid isoform was
more abundant in the cytoplasm than the other isoforms. The
ratio of cytoplasmic to nuclear transcripts is lower in HD fibro-
blasts than in wild-type fibroblasts for all three isoforms, indi-
cating HTT mRNA shifts to the nucleus in HD, as has been
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Figure 3. PAS-Seq Revealed a Third HTT 30 UTR Isoform Whose Relative Abundance Also Changes in HD
(A) PAS-Seq library preparation.
(B) PAS-Seq data analysis on Tbr1, a gene with two 30 UTR isoforms. See also Figure S1.
(legend continued on next page)
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reported (de Mezer et al., 2011). To test HTT 30 UTR isoform sta-
bility, we incubated SH-SY5Y cells with labeled uridine, and we
collected labeled mRNA at various times after washing away the
modified nucleotide. Isoform-specific qRT-PCR revealed allHTT
isoforms have significantly different half-lives; the short isoform
is most stable, whereas the mid isoform is least stable (Fig-
ure 4B). These findings suggest that altered HTT 30 UTR isoform
abundance in HD results in changes in total HTTmRNA localiza-
tion and stability.
Differences in HTT 30 UTR isoform metabolisms could be due
to different polyA tail lengths, microRNA sites, or RNA-binding
protein sites (Di Giammartino et al., 2011; Norbury, 2013). To
determine the polyA tail length of the isoforms, we added an
adaptor to the 30 end of the polyA tail that was used as a priming
site during isoform-specific PCR. Products were resolved on a
gel, enabling quantification of the polyA tail (Figure 4C).We found
the HTT short isoform had a polyA tail length of 50–80 nt in both
SH-SY5Y cells and in HD and control fibroblasts, whereas the
HTT mid and long isoforms had polyA tail lengths of about 5
and 10 nt (Figures 4D and S2C). Studies show mRNA stability
and translation rate drop as the polyA tail decreases below
20 nt (Chang et al., 2014; Park et al., 2016). The short polyA tail
length of the mid and long HTT isoforms may explain their low
half-lives compared to the short isoform.
We used the program TargetScan to identify putative
microRNA sites in the HTT 30 UTR (Lewis et al., 2003). We found
several microRNAs expressed in human brain with sites
exclusive to the mid and long HTT 30 UTR (Figure 4E). To test if
these microRNAs regulate HTT isoform abundance, we trans-
fected SH-SY5Y cells with mimics of microRNAs 221, 137, or
both. MicroRNA 137 exclusively binds the long isoform, while
microRNA 221 has an 8-mer binding site in the long isoform
and a 6-mer binding site common to the mid and long isoforms.
The microRNA 137 mimic had no effect on isoform abundance,
but transfection of the microRNA 221 or both mimics reduced
the abundance of the long and mid, but not short, isoforms rela-
tive to total HTT or GAPDH (Figures 4F and 4G). These results
show at least one microRNA exclusively degrades the long and
midHTT transcripts, potentially contributing to the lower stability
of these isoforms compared to the short isoform.
To identify RNA-binding protein sites exclusive to the mid
and long isoforms, we used crosslinking immunoprecipitation
sequencing (CLIP-seq) databases (Li et al., 2014; Yang et al.,
2015). We found several brain-expressed RNA-binding proteins
adhere to the HTT 30 UTR (Figure S2D). These RNA-binding pro-
teins may differentially affect the stability and localization of HTT
isoforms. Based on these results, we expect the short isoform is
translated more efficiently than the mid and long isoforms due to
its longer polyA tail and increased stability. Indeed, a study
published during the preparation of this paper found the short
HTT 30 UTR isoform may be translated more efficiently than the
long isoform (Xu et al., 2017).
Many Other Genes Exhibit Changes in Isoform
Abundance
We studied whether alterations in mRNA isoform expression are
unique to HTT or features of many genes in HD. To assay tran-
scriptome-wide isoform expression, we performed PAS-Seq
on motor cortex from grade 1 HD brains (n = 6) versus controls
(n = 5) and cerebellum from grade 2–4 patient brains (n = 9)
versus controls (n = 7). We identified genes with multiple
30 UTR isoforms, and we normalized isoform expression to
gene expression. We compared the normalized isoform expres-
sion between HD and control samples.
PAS-Seq uses oligo(dT) to capture polyA tails during reverse
transcription. Oligo(dT) also anneals to genomic polyA stretches.
These genomic sites are artifacts that can lead to overestimation
of the number of alternatively polyadenylated genes, and we dis-
carded them from our analysis (Sheppard et al., 2013). We found
the number of alternatively polyadenylated genes in our data
(about 30%; Figure S3) is similar to that obtained via the
poly(A)-position profiling by sequencing (3Pseq) 30 sequencing
method, which avoids oligo(dT) priming (Jan et al., 2011).
Consistency with 3Pseq data indicates PAS-Seq accurately
captured reads primed from mRNA polyA tails while excluding
reads primed from genomic regions.
In the motor cortex, 11% of alternatively polyadenylated
genes showed a significant (false discovery rate <10%) change
in abundance of at least one 30 UTR isoform in HD (Figure 5A).
Many isoform relative abundances changed over 25% in HD
motor cortex versus controls, indicating a major shift in
isoform expression for the corresponding gene (Figure 5B). In
the cerebellum, none of the alternatively polyadenylated genes
showed a significant change in abundance of at least one iso-
form (Figure 5C). The false discovery rate threshold corrects for
false positives due to multiple testing but may reject true pos-
itives. To allow comparison of isoform changes between motor
cortex and cerebellum, we also included a more sensitive p
value threshold (p < 0.01). Using this threshold, 13% of alterna-
tively polyadenylated genes exhibited isoform changes in HD
motor cortex, whereas 5% of genes exhibited changes in cer-
ebellum. Isoform abundance changes in the cerebellum were
not as large as in the motor cortex (Figure 5D). These results
indicate many genes alter their 30 UTR isoform abundances in
HD motor cortex, whereas changes in the cerebellum are
negligible.
(C) HTT 30 UTR PAS-Seq peak coordinates in HD patient and control cerebellum (CB) and motor cortex (MCx) and in Q140 and wild-type (WT) mouse
striatum (Str).
(D) Alignment of the human (top) and murine (bottom) HTT 30 UTR around the 30 UTR isoform polyA signals (blue) and sites (yellow).
(E) NCBI BLAST alignment score of the human and mouse HTT 30 UTR. Arrows indicate polyA sites.
(F) HTT mid 30 UTR isoform 30-sequencing reads relative to total HTT 30 UTR reads across human tissues and cells.
(G and H) HTT 30 UTR isoform read counts in HD motor cortex (G) or cerebellum (H) compared to controls, normalized to sequencing depth (*p < 0.05).
(I) Total HTT read counts in HD motor cortex or cerebellum compared to controls.
(J) HTT isoform read counts in HD motor cortex (left) or cerebellum (right) compared to controls, normalized to sequencing depth (top) or total HTT expression
(bottom).
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Figure 4. HTT 30 UTR Isoforms Are Metabolized Differently
(A) Ratio of cytoplasmic to nuclear HTT 30 UTR isoform expression, measured by qPCR. Data points are the average of triplicates with SD (*p < 0.05, **p < 0.005,
and ***p < 0.0005).
(B) Relative abundance of labeled HTT 30 UTR isoforms in SH-SY5Y cells after a labeled uridine pulse, measured by qPCR. Data points are the average of
triplicates with SD.
(C) PolyA tail length assay.
(D) Agarose gel of PCR products from the polyA tail length assay.
(legend continued on next page)
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Neurons die and glia proliferate in the HD brain (Vonsattel and
DiFiglia, 1998). Neuronal loss and gliosis are limited in motor cor-
tex from grade 1 brains (Thu et al., 2010). However, it is possible
some or all isoform changes we see are due to changes in cell
populations. We found isoform abundance is highly correlated
(r = 0.87) between the motor cortex and cerebellum despite
the different cell milieu and trace neuronal loss in the cerebellum
(Figure S4). Previous studies that used HD caudate, which suf-
fers extensive neuronal loss (50%–95%), have demonstrated
mRNA expression is similar in HD caudate tissue and HD
caudate neurons (Hodges et al., 2006). These results suggest
the isoform changes we observe in HD motor cortex are not
solely due to neuronal loss.
To determine whether genes with significant (p < 0.01) isoform
changes shifted toward longer or shortermRNA 30 UTR isoforms,
we calculated a weighted change (see the Experimental Proced-
ures). If the weighted change is positive, the gene shifts toward
longer mRNA isoforms in HD patients, whereas if it is negative,
the gene shifts toward shorter isoforms. We found 129 genes
shifted toward longer isoforms in HD motor cortex, whereas
110 genes shifted toward shorter isoforms (Figure 5E). In the cer-
ebellum, 31 genes shifted to the longer isoform whereas 83
shifted to the shorter isoform (Figure 5F). We compared signifi-
cant (p < 0.01) isoform changes in the motor cortex and cere-
bellum. Only 11 genes exhibited mRNA 30 UTR isoform shifts in
both brain areas (Figure 5G, purple). These findings indicate
that there is no generalized trend toward longer or shorter
30 UTR isoforms in HD and isoform alterations are region
specific.
To identify the affected pathways, we performed gene
ontology (GO) analysis on genes with significant (p < 0.01) iso-
form changes (Figure 5H). We found several pathways that
have been reported to be enriched among genes differentially
expressed in HD, including cytokine signaling and production,
RNA polymerase II transcription, translation, calcium signaling,
vesicle-mediated transport, microtubule organization, and DNA
binding (Hodges et al., 2006; Labadorf et al., 2015). Some
enriched pathways are thought to be involved in HD pathogen-
esis, including calcium signaling, cytokine signaling, histone
acetylation, transcription factor binding, axonal transport,
synaptic vesicle localization, dendritic spine morphogenesis,
microtubule organizing, and phagocytic vesicles (Ellrichmann
et al., 2013; Martinez-Vicente et al., 2010; Moumne´ et al.,
2013; Trushina et al., 2003; Zuccato et al., 2010). Aberrant
30 UTR isoform expression may influence pathogenesis in these
disease pathways.
Most Genes with Isoform Changes in HD Are Not
Differentially Expressed
Widespread gene expression changes are reported in the cortex
of late-stage HD patients (Hodges et al., 2006; Labadorf et al.,
2015). We sought to determine if the extensive 30 UTR isoform
changes in HD motor cortex co-occur with gene expression
changes. To measure steady-state gene expression, we com-
bined all PAS-Seq reads from each gene (see the Experimental
Procedures). Consistent with previous studies, many genes
were differentially expressed in HD patient motor cortex relative
to controls (false discovery rate <10%) (Figure 6A) (Hodges et al.,
2006; Labadorf et al., 2015). qPCR confirmed differential
expression of three genes (Figure S5). Of differentially expressed
genes, 700 exhibited increased expression in HD motor cortex,
whereas 1,008 exhibited decreased expression (Figure 6C).
The percentage of detected genes exhibiting expression
changes was identical to the percentage of alternatively polya-
denylated genes exhibiting isoform changes (11%). In contrast,
only 1% of genes were differentially expressed (false discovery
rate <10%) in patient cerebellum (Figure 6B). Of differentially
expressed genes, 89 increased expression in HD patient
cerebellum whereas 64 decreased (Figure 6D). Thus, isoform
changes are proportional to gene expression changes in the
HD motor cortex, whereas isoform and gene expression
changes are minimal in the cerebellum.
To determine if genes with isoform changes also exhibit
expression changes, we compared gene expression to isoform
expression for all the alternatively polyadenylated genes using
a significance cutoff of p < 0.01 (Figures 6E and 6F). In the motor
cortex, only 17% of genes with isoform shifts were differentially
expressed (Figure 6E, red). Of genes exhibiting isoform and gene
expression changes, we found no association between isoform
shift and gene expression direction. This dissociation of isoform
and gene expression is consistent with studies showing the rela-
tionship between 30 UTR length and isoform stability is gene spe-
cific (Spies et al., 2013). In the cerebellum, only 4% of genes with
significant isoform changes were differentially expressed (Fig-
ure 6F, red). These results indicate that most genes with isoform
changes are not differentially expressed in HD motor cortex and
cerebellum.
We sought to determine if isoform and gene expression
changes are associated with common cell pathways. We found
several ontology categories enriched among genes with isoform
changes and genes with expression changes, including mRNA
30 UTR binding, cell junction, ubiquitination, mRNA binding,
and protein transport (Figures 5G, 5H, 6G, and 6H). Within
each category, genes with isoform differences and genes with
expression changes did not overlap, i.e., the same gene did
not exhibit aberrant isoform and gene expression. Isoform alter-
ations and gene expression changes are separate, but they may
affect common processes in HD brains.
Decreasing Expression of the RNA-Binding Protein
CNOT6 Leads Some Genes to Change Isoform
Abundance
A change in the expression of an RNA-binding protein may lead
to changes in isoform abundance by altering isoform production
or decay. To identify candidate RNA-binding proteins, we
searched for genes differentially expressed in HD motor cortex
(E) Brain-expressed microRNA sites in the HTT 30 UTR.
(F and G) Fold change in expression ofHTT 30 UTR isoforms relative to totalHTT (F) orGAPDH (G) expression between SH-SY5Y cells transfected withmicroRNA
mimics (miRs) targetingHTT or a non-targeting (NT) control, measured by qPCR. Data points are the average of triplicates with SD. The siRNA is targeting theHTT
open reading frame. See also Figure S2.
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Figure 5. Transcriptome-wide PAS-Seq Analysis Identifies a Large Subset of Genes with 30 UTR Isoform Changes in HD Motor Cortex
(A) Scatterplot of PAS-Seq reads from control (n = 5) and HD (n = 6) motor cortex. Each dot is a 30 UTR isoform. Shown is the number of isoform reads divided by
the gene’s total 30 UTR reads (isoform fraction). Orange and red dots indicate isoforms with p < 0.01 or false discovery rate <10%, respectively.
(B) Volcano plot of reads from control and HD motor cortex, colors as in (A). The percentage change is the difference in the isoform fraction between HD and
control samples, multiplied by 100.
(C) Scatterplot of PAS-Seq reads from control (n = 7) and HD (n = 9) cerebellum, as in (A). Green dots indicate isoforms with p < 0.01.
(D) Volcano plot of reads from control and HD cerebellum, with colors as in (C).
(E and F) Heatmap of the weighted change of genes with one or more isoform differentially expressed (p < 0.01) in patient motor cortex (E) or cerebellum (F).
A positive number indicates the gene shifts toward longer isoforms in HD, whereas a negative number indicates the gene shifts toward shorter isoforms.
(legend continued on next page)
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with the RNA-binding protein GO term (Figure 7A). Of those, 20
were involved in mRNA alternative polyadenylation or stability.
We reasoned that an RNA-binding protein responsible for HTT
isoform shifts would show opposite expression changes in HD
motor cortex and cerebellum. Of nine with opposite expression
changes, two (CNOT6 and CNOT7) are subunits of the Ccr4-
not complex that plays a widespread role in mRNA metabolism
(Mittal et al., 2011; Shirai et al., 2014). CNOT6, the subunit that
catalyzes deadenylation of mRNAs, is most differentially ex-
pressed in HD motor cortex and cerebellum (Yamashita et al.,
2005).
To determine if changes in CNOT6 expression exert changes
in isoform expression, we transfected control human fibroblasts
with small interfering RNAs (siRNAs) targeting CNOT6 or an off-
target control (MAP4K4). The CNOT6 siRNAs reduced CNOT6
mRNA expression over 80% but did not affect total HTT mRNA
levels (Figures 7B and 7C). We chose HTT and SECISBP2L
(SECIS Binding Protein 2 Like) as candidate CNOT6 targets.
HTT and SECISBP2L shift to longer 30 UTR isoforms in HD cere-
bellum and shorter isoforms in HD motor cortex. Knockdown
of CNOT6 resulted in a relative decrease in the HTT and
SECISBP2L long isoforms, similar to that seen in HD patient
motor cortex and in HD fibroblasts (Figure 7D). HTT isoform-
specific qRT-PCR revealed that the abundance of the short iso-
form didn’t change, whereas abundance of the long isoform
decreased by almost 2-fold, as in HD patient motor cortex (Fig-
ure 7E). These results suggest changes in the expression of
CNOT6 may influence the abundance of some 30 UTR isoforms
in HD patient motor cortex and cerebellum.
DISCUSSION
Widespread changes in isoform abundancemay lead to aberrant
mRNA metabolism in HD. Some 30 UTR isoforms exhibit unique
localizations and functions. The long, but not short, isoform of
brain-derived neurotrophic factor mRNA is translated in den-
drites, where the protein is vital for pruning and spine enlarge-
ment (An et al., 2008). The long isoform of CD47 mRNA acts as
a scaffold for proteins that translocate the CD47 protein to the
cell membrane, whereas the short isoform localizes the protein
to the endoplasmic reticulum (Berkovits and Mayr, 2015). Loss
of normal 30 UTR isoform abundance can contribute to disease.
The alpha synuclein long isoform is localized to mitochondria;
increased abundance of the extended alpha synuclein mRNA
may contribute to mitochondrial dysfunction in Parkinson’s dis-
ease (Rhinn et al., 2012). Many genes in cancer cells shift toward
more stable isoforms, increasing translation of tumorigenic pro-
teins (Mayr and Bartel, 2009). In myotonic dystrophy, triplet
repeat RNAs sequester muscleblind, a regulator of 30 UTR
length, resulting in an altered polyadenylation profile (Batra
et al., 2014). We demonstrate that genes with isoform changes
in HD motor cortex are associated with pathways disrupted in
HD. Altered metabolism of mRNAs in disease pathways could
result in aberrant localization or function of proteins and
contribute to HD pathogenesis.
Altered expression of RNA-binding proteins in the HD brain
may lead to changes in the expression ofmRNA 30 UTR isoforms.
RNA-binding proteins may interact with nascent mRNA during
transcription and alternative polyadenylation, resulting in
changes in polyA site selection and isoform production. For
instance, aberrant expression of 30 end modulatory factors
may lead to isoform abundance changes (Gruber et al., 2014).
We found three 30 end-processing proteins are differentially ex-
pressed in HD grade 1 motor cortex: CPSF2, PCBP2, and
THOC5. RNA-binding proteins may also adhere to isoforms
post-transcriptionally, affecting the stability and decay of iso-
forms and leading to changes in isoform abundance. We show
a decrease in the CNOT6 deadenylase is associated with a
decrease in the HTT long isoform but no change in the short or
mid isoforms. Further studies are necessary to determine the
mechanism of 30 UTR isoform changes in HD. We found HTT
and SECISBP2L isoform amounts are responsive to changes in
CNOT6 mRNA levels. However, altered CNOT6 expression in
HD may not explain all isoform changes we identified. Other
RNA-binding proteins, such as 30 end-processing factors, likely
affect isoform abundance in HD. Exploration of the causes of iso-
form changes in HDmotor cortex may result in novel therapeutic
targets.
Our findings have important implications for HD andmay apply
to other diseases. The increased relative abundance of the HTT
short isoform in HD motor cortex might contribute to pathology;
a study published during the preparation of this paper found
transfected HTT exon 1-short 30 UTR constructs form more ag-
gregates than exon 1-long 30 UTR constructs (Xu et al., 2017).
New therapies aim to disrupt the mutant, but not wild-type,
HTT mRNA by targeting SNPs heterozygous in patients (Øster-
gaard et al., 2013; Pfister et al., 2009). Our results suggest target-
ing SNPs exclusive to the long isoformmay be less effective than
targeting SNPs common to all isoforms, as HTT long isoform
abundance is reduced in HD patient motor cortex. Further
research is necessary to determine if isoform alterations are
unique to HD or if they frequently accompany gene expression
changes in human disease.
EXPERIMENTAL PROCEDURES
Samples
Human samples were supplied by the New York and Neurological Foundation
of New Zealand brain banks. Fibroblast lines were obtained from the Coriell
Repository. Mouse tissues were dissected from 7- to 9-month-old male and
female mice. All protocols were reviewed and approved by the institutional
biosafety committee (human samples) or institutional animal care and use
committee (mouse samples).
Public 30 Sequencing Data Analysis
Raw 30 sequencing data were downloaded from NCBI short Sequence Read
Archive (SRA): SRP029953 (Lianoglou et al., 2013) and analyzed as below.
(G) Comparison of gene-weighted changes between patient versus control motor cortex (MCx) and cerebellum (CB). Green and orange dots have significant
changes in HD cerebellum and motor cortex, respectively, and purple dots have both (p < 0.01).
(H) Gene ontology analysis of genes exhibiting significant (p < 0.01) shifts to longer (long) or shorter (short) isoforms in HDmotor cortex (MCx) and cerebellum (CB).
See also Figures S3 and S4.
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Figure 6. Gene Expression Analysis Shows Most Genes with 30 UTR Isoform Changes Do Not Exhibit Expression Changes in HD
(A) Scatterplot of gene expression normalized to sequencing depth in control (n = 5) and HD (n = 6) motor cortex, measured by PAS-Seq. Orange and red dots
indicate genes with p < 0.01 or false discovery rate <10%, respectively.
(B) Scatterplot of gene expression from control (n = 7) and HD (n = 9) cerebellum, as in (A). Green and blue dots indicate isoforms with p < 0.01 or false discovery
rate <10%, respectively.
(C and D) Heatmap of genes significantly differentially expressed (false discovery rate <10%) in patient motor cortex (C) or cerebellum (D). Shown are the fold
changes in normalized gene expression.
(E) Comparison of gene isoform-weighted changes and differential expression (DE) log 2 fold changes in HD versus control motor cortex. Green and orange dots
have significant isoform or expression changes in HD, respectively, and red dots have both (p < 0.01).
(F) Comparison of gene isoform-weighted changes and expression log 2 fold changes in HD versus control cerebellum, as in (E).
(legend continued on next page)
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RNA Extraction
Total RNA was extracted with Trizol (Ambion), cleaned on Clean and Concen-
trator columns (ZymoGenetics), analyzed via Bioanalyzer (Agilent Technolo-
gies), and treated with TurboDNase (Ambion).
qRT-PCR
RNA was reverse-transcribed by SuperScript IV (Invitrogen). The qPCR was
performed byQIAGENQuantiFast SYBR greenmastermix (non-allele specific)
or QIAGEN 13 Type-it Fast SNP PCR master mix (allele specific). Product
amounts were calculated using the DDCt method. Primer and probe se-
quences are listed in the Supplemental Experimental Procedures.
Nuclear and Cytoplasmic Isoform Abundance
SH-SY5Y cell (ATCC) nuclear and cytoplasmic RNA fractions were collected
as described in the Supplemental Experimental Procedures, and RNA was
submitted to isoform-specific qRT-PCR.
(G) Comparison of gene expression log 2 fold changes in motor cortex (MCx) and cerebellum (CB). Red and blue dots have significant expression changes in HD
motor cortex or cerebellum, respectively, and light blue dots have both (false discovery rate <10%).
(H) Gene ontology analysis of genes with significant (false discovery rate <10%) expression changes in HD motor cortex (MCx) and cerebellum (CB). See also
Figures S4 and S5.
Figure 7. Changes in the Expression of RNA-Binding Proteins May Influence Alterations in Isoform Abundances
(A) Algorithm to identify proteins that may cause 30 UTR isoform changes in HD. Numbers are fold changes (FCs) in gene expression between HD and control
motor cortex (MCx) or cerebellum (CB).
(B) Fold change inCNOT6expression relative toGAPDHexpressionafter transfectionofCNOT6siRNA (gray), nosiRNA (white), or non-targeting (NT)MAP4K4control
siRNA (black) into wild-type fibroblasts, measured by qPCR (*p < 0.05, **p < 0.005, and ***p < 0.0005). Shown is the average of at least three transfections with SD.
(C) Fold change in total HTT expression relative to GAPDH expression after transfection, as in (B).
(D) Fold change in expression of the HTT long isoform (long) relative to total HTT expression (total) or of the SECISBP2L long isoform (long) relative to total
SECISBP2L expression (total) after transfection, as in (B). Red and blue bars are untreated fibroblasts.
(E) Fold change in eachHTT isoform isoform (long) relative to totalHTT expression after transfection ofCNOT6 siRNA (colored), no siRNA (white), or non-targeting
(NT) MAP4K4 control siRNA (black) into wild-type fibroblasts.
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EU Pulse Chase and Isoform-Specific qRT-PCR
SH-SY5Y cells (ATCC) were pulsed in 200 mM 5-ethynyluridine (EU) for 14 hr,
washed in PBS, and chased with unmodified media. We isolated labeled RNA
using the Click-iT Nascent RNA Capture Kit (Life Technologies) as detailed in
the Supplemental Experimental Procedures. qRT-PCR was performed, and
isoform amounts were normalized to those of a firefly luciferase spike-in.
PolyA Tail Length Assay
The HTT isoform polyA tail lengths were determined using the Affymetrix
PolyA Tail Length Assay, as described in the Supplemental Experimental
Procedures.
MicroRNA and RNA-Binding Protein Target Site Prediction
We used the CLIPdb and starBase v2.0 browsers to identify HTT 30 UTR RNA-
binding protein sites supported by more than five reads (Li et al., 2014; Yang
et al., 2015). Brain expression was confirmed with the human protein atlas
(www.proteinatlas.org) (Uhlen et al., 2015). To identify predicted microRNA
7-mer-1A, 7-mer-m8, 8-mer binding sites, we used TargetScanHuman version
7.0 (Lewis et al., 2003). Brain expression was confirmed with miRmine Human
miRNA Expression Database (Panwar et al., 2017).
MicroRNA Transfection
SH-SY5Y cells (ATCC) were transfected with mimics (Dharmacon) to
microRNAs 137, 221, a C. elegans microRNA, or an HTT open reading frame
(ORF)-targeting siRNA via Lipofectamine RNAimax (Invitrogen). After 72 hr,
RNA was extracted and submitted to qRT-PCR.
PAS-Seq Library Preparation
For details, see the Supplemental Experimental Procedures. Briefly, RNA was
fragmented and reverse-transcribed by Superscript III (Invitrogen) from the
PAS-Seq oligo d(T) primer. cDNA fragments 160–200 nt long were circularized
by CircLigase II (Epicenter), and Phusion polymerase (New England Biolabs)
amplified the cDNA and adaptors with PE 1.0 and PE 2.0 primers (Illumina).
The 215- to 254-nt library was size-selected via gel electrophoresis and sub-
jected to single-end 100 base-pair sequencing.
PAS-Seq Analysis
For details, see the Supplemental Experimental Procedures. Briefly, se-
quences were mapped to the genome, and reads corresponding to the
same 30 UTR isoform were combined. We removed genomically primed reads
and normalized isoform expression to gene expression. For isoforms repre-
sented in at least five samples, the normalized abundance was compared
between HD and control samples. To calculate the isoform-weighted change
for each gene, we weighed isoform fractions by the isoform ordinal number
multiplied by ten, and we determined the difference in the average weighted
isoform fractions between HD and control samples. For differential gene
expression analysis, the total reads mapping to each gene were compared be-
tween patients and controls using DESeq2 (Love et al., 2014). We considered
genes with a change >50% and false discovery rate <10% significantly differ-
ently expressed.
Gene Ontology Analysis
The list of genes with significant changes in total or 30 UTR isoform expression
in HD brains was compared to the background total or alternatively polyade-
nylated expressed genes using Panther (Mi et al., 2013). We considered
categories enriched if they had five or more genes, enrichment greater than
1.5-fold, and p < 0.01.
CNOT6 siRNA Transfection
Wild-type fibroblasts were transfected with three siRNAs targeting CNOT6 or
MAP4K4 (QIAGEN FlexiTube) via Lipofectamine RNAimax (Invitrogen). After
72 hr, RNA was extracted and submitted to qRT-PCR.
Statistical Methods
Two-tailed t tests were used to determine statistical significance for all figures
except Figure 4, where an ANOVA test was used, and Figure 6, where DESeq2
was used for differential gene expression analysis (Love et al., 2014). p < 0.05
was considered significant unless otherwise stated.
Data and Software Availability
The accession number for the PAS-Seq data reported in this paper is GEO:
GSE96099. The PAS-Seq data analysis pipeline can be accessed at http://
dx.doi.org/10.17632/99gfdrgbxc.2.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2017.09.009.
AUTHOR CONTRIBUTIONS
L.R. and N.A. conceived the project. L.R. and E.P. designed the experiments.
L.R. performed the experiments and interpreted results. A.A.-P. designed the
PAS-Seq method. L.R. wrote the manuscript with comments from all authors.
ACKNOWLEDGMENTS
We thank the M. DiFiglia lab (Massachusetts General Hospital) for providing
neural stem cell pellets, X.W. Yang (University of California Los Angeles) for
supplying null Httmice, M. Hayden (University of British Columbia and Center
for Molecular Medicine and Therapeutics) for supplying Yac18 mice, and the
Cure Huntington’s Disease Initiative for supplying Q140 mice. We thank the
New York and Neurological Foundation of New Zealand brain banks for sup-
plying human samples. A. Bicknell provided the EU pulse-chase protocol,
and J. Alterman provided the HTT-targeitng siRNA. S. Yang and C. Smith as-
sisted with allele-specific qPCR. K. Chase, F. Conroy, and R. Miller performed
mouse husbandry and genotyping. We thank S. Ryder, S. Corvera, V. Budnik,
and A. Jacobson for their comments on experimental design. This study was
supported by NIH grant 5 RO1 NS038194-15 (N.A.), NIH NINDS grant 1 F30
NS095450-01 (L.R.), and private donations. The content is solely the respon-
sibility of the authors and does not necessarily represent the official views of
the NIH.
Received: March 22, 2017
Revised: July 14, 2017
Accepted: August 31, 2017
Published: September 26, 2017
REFERENCES
An, J.J., Gharami, K., Liao, G.-Y., Woo, N.H., Lau, A.G., Vanevski, F., Torre,
E.R., Jones, K.R., Feng, Y., Lu, B., and Xu, B. (2008). Distinct role of long
30 UTR BDNFmRNA in spine morphology and synaptic plasticity in hippocam-
pal neurons. Cell 134, 175–187.
Ashar-Patel, A., Kaymaz, Y., Rajakumar, A., Bailey, J.A., Karumanchi, S.A.,
and Moore, M.J. (2017). FLT1 and transcriptome-wide polyadenylation site
(PAS) analysis in preeclampsia. Sci. Rep. http://dx.doi.org/10.1038/s41598-
017-11639-6
Ban˜ez-Coronel, M., Ayhan, F., Tarabochia, A.D., Zu, T., Perez, B.A., Tusi, S.K.,
Pletnikova, O., Borchelt, D.R., Ross, C.A., Margolis, R.L., et al. (2015). RAN
translation in Huntington disease. Neuron 88, 667–677.
Batra, R., Charizanis, K., Manchanda, M., Mohan, A., Li, M., Finn, D.J., Good-
win, M., Zhang, C., Sobczak, K., Thornton, C.A., and Swanson, M.S. (2014).
Loss of MBNL leads to disruption of developmentally regulated alternative
polyadenylation in RNA-mediated disease. Mol. Cell 56, 311–322.
Berkovits, B.D., and Mayr, C. (2015). Alternative 30 UTRs act as scaffolds to
regulate membrane protein localization. Nature 522, 363–367.
Chang, H., Lim, J., Ha, M., and Kim, V.N. (2014). TAIL-seq: genome-wide
determination of poly(A) tail length and 30 end modifications. Mol. Cell 53,
1044–1052.
3068 Cell Reports 20, 3057–3070, September 26, 2017
de Mezer, M., Wojciechowska, M., Napierala, M., Sobczak, K., and Krzyzo-
siak, W.J. (2011). Mutant CAG repeats of Huntingtin transcript fold into hair-
pins, form nuclear foci and are targets for RNA interference. Nucleic Acids
Res. 39, 3852–3863.
Di Giammartino, D.C., Nishida, K., and Manley, J.L. (2011). Mechanisms and
consequences of alternative polyadenylation. Mol. Cell 43, 853–866.
DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P.,
and Aronin, N. (1997). Aggregation of huntingtin in neuronal intranuclear inclu-
sions and dystrophic neurites in brain. Science 277, 1990–1993.
Ellrichmann, G., Reick, C., Saft, C., and Linker, R.A. (2013). The role of the im-
mune system in Huntington’s disease. Clin. Dev. Immunol. 2013, 541259.
Gruber, A.R., Martin, G., Keller, W., and Zavolan, M. (2014). Means to an end:
mechanisms of alternative polyadenylation of messenger RNA precursors.
Wiley Interdiscip. Rev. RNA 5, 183–196.
Hodges, A., Strand, A.D., Aragaki, A.K., Kuhn, A., Sengstag, T., Hughes, G.,
Elliston, L.A., Hartog, C., Goldstein, D.R., Thu, D., et al. (2006). Regional and
cellular gene expression changes in human Huntington’s disease brain.
Hum. Mol. Genet. 15, 965–977.
Hu, J., Liu, J., and Corey, D.R. (2010). Allele-selective inhibition of huntingtin
expression by switching to an miRNA-like RNAi mechanism. Chem. Biol. 17,
1183–1188.
Jan, C.H., Friedman, R.C., Ruby, J.G., and Bartel, D.P. (2011). Formation,
regulation and evolution of Caenorhabditis elegans 3’UTRs. Nature 469,
97–101.
Kovalevich, J., and Langford, D. (2013). Considerations for the use of SH-SY5Y
neuroblastoma cells in neurobiology. Methods Mol. Biol. 1078, 9–21.
Labadorf, A., Hoss, A.G., Lagomarsino, V., Latourelle, J.C., Hadzi, T.C., Bregu,
J., MacDonald, M.E., Gusella, J.F., Chen, J.F., Akbarian, S., et al. (2015). RNA
sequence analysis of human huntington disease brain reveals an extensive in-
crease in inflammatory and developmental gene expression. PLoS ONE 10,
e0143563.
Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P., and Burge, C.B.
(2003). Prediction of mammalian microRNA targets. Cell 115, 787–798.
Li, L.-B., Yu, Z., Teng, X., and Bonini, N.M. (2008). RNA toxicity is a component
of ataxin-3 degeneration in Drosophila. Nature 453, 1107–1111.
Li, J.H., Liu, S., Zhou, H., Qu, L.H., and Yang, J.H. (2014). starBase v2.0: de-
coding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks
from large-scale CLIP-Seq data. Nucleic Acids Res. 42, D92–D97.
Lianoglou, S., Garg, V., Yang, J.L., Leslie, C.S., and Mayr, C. (2013). Ubiqui-
tously transcribed genes use alternative polyadenylation to achieve tissue-
specific expression. Genes Dev. 27, 2380–2396.
Lin, B., Rommens, J.M., Graham, R.K., Kalchman, M., MacDonald, H., Nasir,
J., Delaney, A., Goldberg, Y.P., and Hayden, M.R. (1993). Differential 30 poly-
adenylation of the Huntington disease gene results in two mRNA species with
variable tissue expression. Hum. Mol. Genet. 2, 1541–1545.
Lin, L., Park, J.W., Ramachandran, S., Zhang, Y., Tseng, Y.-T., Shen, S., Wald-
vogel, H.J., Curtis, M.A., Faull, R.L.M., Troncoso, J.C., et al. (2016). Transcrip-
tome sequencing reveals aberrant alternative splicing in Huntington’s disease.
Hum. Mol. Genet. 25, 3454–3466.
Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold
change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.
Macdonald, M.E., Ambrose, C.M., Duyao, M.P., Myers, R.H., Lin, C., Srinidhi,
L., Barnes, G., Taylor, S.A., James, M., Groat, N., et al.; The Huntington’s
Disease Collaborative Research Group (1993). A novel gene containing a trinu-
cleotide repeat that is expanded and unstable on Huntington’s disease chro-
mosomes. Cell 72, 971–983.
Martinez-Vicente, M., Talloczy, Z., Wong, E., Tang, G., Koga, H., Kaushik, S.,
de Vries, R., Arias, E., Harris, S., Sulzer, D., and Cuervo, A.M. (2010). Cargo
recognition failure is responsible for inefficient autophagy in Huntington’s dis-
ease. Nat. Neurosci. 13, 567–576.
Mayr, C., and Bartel, D.P. (2009). Widespread shortening of 30UTRs by alterna-
tive cleavage and polyadenylation activates oncogenes in cancer cells. Cell
138, 673–684.
Menalled, L.B., Sison, J.D., Dragatsis, I., Zeitlin, S., and Chesselet, M.-F.
(2003). Time course of early motor and neuropathological anomalies in a
knock-in mouse model of Huntington’s disease with 140 CAG repeats.
J. Comp. Neurol. 465, 11–26.
Mi, H., Muruganujan, A., and Thomas, P.D. (2013). PANTHER in 2013:
modeling the evolution of gene function, and other gene attributes, in the
context of phylogenetic trees. Nucleic Acids Res. 41, D377–D386.
Mittal, S., Aslam, A., Doidge, R., Medica, R., and Winkler, G.S. (2011). The
Ccr4a (CNOT6) and Ccr4b (CNOT6L) deadenylase subunits of the human
Ccr4-Not complex contribute to the prevention of cell death and senescence.
Mol. Biol. Cell 22, 748–758.
Moumne´, L., Betuing, S., and Caboche, J. (2013). Multiple aspects of gene
dysregulation in Huntington’s disease. Front. Neurol. 4, 127.
Mykowska, A., Sobczak, K., Wojciechowska, M., Kozlowski, P., and Krzyzo-
siak, W.J. (2011). CAG repeats mimic CUG repeats in the misregulation of
alternative splicing. Nucleic Acids Res. 39, 8938–8951.
Norbury, C.J. (2013). Cytoplasmic RNA: a case of the tail wagging the dog.
Nat. Rev. Mol. Cell Biol. 14, 643–653.
Østergaard, M.E., Southwell, A.L., Kordasiewicz, H., Watt, A.T., Skotte, N.H.,
Doty, C.N., Vaid, K., Villanueva, E.B., Swayze, E.E., Bennett, C.F., et al. (2013).
Rational design of antisense oligonucleotides targeting single nucleotide poly-
morphisms for potent and allele selective suppression of mutant Huntingtin in
the CNS. Nucleic Acids Res. 41, 9634–9650.
Panwar, B., Omenn, G.S., and Guan, Y. (2017). miRmine: a database of human
miRNA expression profiles. Bioinformatics 33, 1554–1560.
Park, J.E., Yi, H., Kim, Y., Chang, H., and Kim, V.N. (2016). Regulation of
poly(A) tail and translation during the somatic cell cycle. Mol. Cell 62, 462–471.
Pfister, E.L., Kennington, L., Straubhaar, J., Wagh, S., Liu, W., DiFiglia, M.,
Landwehrmeyer, B., Vonsattel, J.-P., Zamore, P.D., and Aronin, N. (2009).
Five siRNAs targeting three SNPs may provide therapy for three-quarters of
Huntington’s disease patients. Curr. Biol. 19, 774–778.
Rhinn, H., Qiang, L., Yamashita, T., Rhee, D., Zolin, A., Vanti, W., and Abelio-
vich, A. (2012). Alternative a-synuclein transcript usage as a convergent mech-
anism in Parkinson’s disease pathology. Nat. Commun. 3, 1084.
R€ub, U., Hoche, F., Brunt, E.R., Heinsen, H., Seidel, K., Del Turco, D., Paulson,
H.L., Bohl, J., von Gall, C., Vonsattel, J.P., et al. (2013). Degeneration of the
cerebellum in Huntington’s disease (HD): possible relevance for the clinical
picture and potential gateway to pathological mechanisms of the disease pro-
cess. Brain Pathol. 23, 165–177.
Sandberg, R., Neilson, J.R., Sarma, A., Sharp, P.A., and Burge, C.B. (2008).
Proliferating cells express mRNAs with shortened 30 UTRs and fewer micro-
RNA target sites. Science 320, 1643–1647.
Sathasivam, K., Neueder, A., Gipson, T.A., Landles, C., Benjamin, A.C., Bon-
dulich, M.K., Smith, D.L., Faull, R.L., Roos, R.A., Howland, D., et al. (2013).
Aberrant splicing of HTT generates the pathogenic exon 1 protein in Hunting-
ton disease. Proc. Natl. Acad. Sci. USA 110, 2366–2370.
Sheets, M.D., Ogg, S.C., and Wickens, M.P. (1990). Point mutations in
AAUAAA and the poly (A) addition site: effects on the accuracy and efficiency
of cleavage and polyadenylation in vitro. Nucleic Acids Res. 18, 5799–5805.
Sheppard, S., Lawson, N.D., and Zhu, L.J. (2013). Accurate identification of
polyadenylation sites from 30 end deep sequencing using a naive Bayes clas-
sifier. Bioinformatics 29, 2564–2571.
Shirai, Y.T., Suzuki, T., Morita, M., Takahashi, A., and Yamamoto, T. (2014).
Multifunctional roles of the mammalian CCR4-NOT complex in physiological
phenomena. Front. Genet. 5, 286.
Slow, E.J., van Raamsdonk, J., Rogers, D., Coleman, S.H., Graham, R.K.,
Deng, Y., Oh, R., Bissada, N., Hossain, S.M., Yang, Y.-Z., et al. (2003). Selec-
tive striatal neuronal loss in a YAC128 mouse model of Huntington disease.
Hum. Mol. Genet. 12, 1555–1567.
Smibert, P., Miura, P., Westholm, J.O., Shenker, S., May, G., Duff, M.O.,
Zhang, D., Eads, B.D., Carlson, J., Brown, J.B., et al. (2012). Global patterns
of tissue-specific alternative polyadenylation in Drosophila. Cell Rep. 1,
277–289.
Cell Reports 20, 3057–3070, September 26, 2017 3069
Spies, N., Burge, C.B., and Bartel, D.P. (2013). 30 UTR-isoform choice has
limited influence on the stability and translational efficiency of most mRNAs
in mouse fibroblasts. Genome Res. 23, 2078–2090.
Suchowersky, O. (2014). Huntington disease: clinical features and diagnosis.
UpToDate, https://www.uptodate.com/contents/huntington-disease-clinical-
features-and-diagnosis.
Thu, D.C.V., Oorschot, D.E., Tippett, L.J., Nana, A.L., Hogg, V.M., Synek, B.J.,
Luthi-Carter, R., Waldvogel, H.J., and Faull, R.L.M. (2010). Cell loss in the mo-
tor and cingulate cortex correlates with symptomatology in Huntington’s dis-
ease. Brain 133, 1094–1110.
Tian, B., Hu, J., Zhang, H., and Lutz, C.S. (2005). A large-scale analysis of
mRNA polyadenylation of human and mouse genes. Nucleic Acids Res. 33,
201–212.
Trushina, E., Heldebrant, M.P., Perez-Terzic, C.M., Bortolon, R., Kovtun, I.V.,
Badger, J.D., 2nd, Terzic, A., Este´vez, A., Windebank, A.J., Dyer, R.B., et al.
(2003). Microtubule destabilization and nuclear entry are sequential steps
leading to toxicity in Huntington’s disease. Proc. Natl. Acad. Sci. USA 100,
12171–12176.
Uhlen, M., Fagerberg, L., Hallstrom, B.M., Lindskog, C., Oksvold, P., Mardino-
glu, A., Sivertsson, A., Kampf, C., Sjostedt, E., Asplund, A., et al. (2015). Pro-
teomics. Tissue-based map of the human proteome. Science 347, 1260419.
Vonsattel, J.P.G. (2008). Huntington disease models and human neuropa-
thology: similarities and differences. Acta Neuropathol. 115, 55–69.
Vonsattel, J.P.G., and DiFiglia, M. (1998). Huntington disease. J. Neuropathol.
Exp. Neurol. 57, 369–384.
Vonsattel, J.-P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D., and Ri-
chardson, E.P., Jr. (1985). Neuropathological classification of Huntington’s
disease. J. Neuropathol. Exp. Neurol. 44, 559–577.
Xu, H., An, J.J., and Xu, B. (2017). Distinct cellular toxicity of two mutant hun-
tingtin mRNA variants due to translation regulation. PLoS ONE 12, e0177610.
Yamashita, A., Chang, T.-C., Yamashita, Y., Zhu, W., Zhong, Z., Chen, C.-Y.,
and Shyu, A.B. (2005). Concerted action of poly(A) nucleases and decapping
enzyme in mammalian mRNA turnover. Nat. Struct. Mol. Biol. 12, 1054–1063.
Yang, Y.-C.T., Di, C., Hu, B., Zhou, M., Liu, Y., Song, N., Li, Y., Umetsu, J., and
Lu, Z.J. (2015). CLIPdb: a CLIP-seq database for protein-RNA interactions.
BMC Genomics 16, 51.
Zeitlin, S., Liu, J.-P., Chapman, D.L., Papaioannou, V.E., and Efstratiadis, A.
(1995). Increased apoptosis and early embryonic lethality in mice nullizygous
for the Huntington’s disease gene homologue. Nat. Genet. 11, 155–163.
Zhang, H., Lee, J.Y., and Tian, B. (2005). Biased alternative polyadenylation in
human tissues. Genome Biol. 6, R100.
Zuccato, C., Valenza, M., and Cattaneo, E. (2010). Molecular mechanisms and
potential therapeutical targets in Huntington’s disease. Physiol. Rev. 90,
905–981.
3070 Cell Reports 20, 3057–3070, September 26, 2017
